https://www.selleckchem.com/pr....oducts/ll37-human.ht
The evidence supporting the efficacy of these agents is mainly derived from small, uncontrolled trials. A notable recent advance is the discovery of IL36RN mutations and the central role of IL-36 receptor ligands in the pathogenesis of GPP, which has defined key therapeutic targets for the disease. Biologic agents that target the IL-36 pathway have demonstrated promising efficacy in patients with GPP, marking the beginning of a new era of targeted therapy for GPP. Generalized pustular psoriasis (GPP) is a rare disease characterized b
Aimer
Commentaire
Partagez
